Skip to main content
Premium Trial:

Request an Annual Quote

Thomson Reuters, NuMedii Ink Partnership Around Drug Repurposing


Thomson Reuters and NuMedii this week announced a partnership that will pair NuMedii's underlying informatics technology with curated drug and disease information and systems biology expertise from Thomson Reuters for use in identifying new applications for existing drugs.

Specifically, NuMedii will combine content from Thomson Reuters MetaCore and Integrity repositories with its technology — based on machine learning, pattern matching, and network biology algorithms — and use it to find FDA-approved drugs or discontinued development compounds that are appropriate for repurposing.

"This unique partnership allows NuMedii access to an unparalleled source of knowledge from Thomson Reuters, enabling us to turbo-charge our search and discovery of new applications for existing therapies," according to Gini Deshpande, founder and chief executive officer of NuMedii.

It's also an opportunity to “combine the leading information sources available with novel analytics, data integration, and biomedical expertise in a way that has not been done before outside of a laboratory environment,” Joe Donahue, senior vice president of Thomson Reuters Life Sciences, said in a statement.